ClinicalTrials.gov
public full text
Public Domain
A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients
The goal of the study is to investigate whether adding sulforaphane will benefit the negative symptoms and cognitive function in individuals who have schizophrenia. This study will compare the sulforaphane with placebo. There is a thirty percent change (less than half) of receiving the placebo. The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Efficacy of Treating First Episode Psychosis With Folic Acid,B12 and B6 in Addition to Antipsychotic Medication#917966
- Minocycline for the Treatment of Early-Phase Schizophrenia#1046902
- The Effects of Varenicline on Cognitive Function in Patients With Schizophrenia#875471
- Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis#911998
- D-serine for Posttraumatic Stress Disorder Treatment#1047665
Record · ID 827155
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive